{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:44Z","timestamp":1790889944669,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This article aims to describe the current diagnostic and therapeutic practices for managing chronic rhinosinusitis with nasal polyps (CRSwNP) among Austrian ENT specialists. A cross-sectional, nationwide survey was conducted between November and December 2022 in Austria. A total of 50 ENT specialists, evenly split between hospital- and office-based physicians, participated. The questionnaire covered demographics, diagnostic and therapeutic approaches. CT imaging, nasal endoscopy, and blood eosinophil count were the most utilized diagnostic tools. Most participants applied the SNOT-22 for patient-reported outcomes. Local corticosteroids were the most frequently prescribed treatment. Systemic corticosteroid overuse and limited biologic adoption were noted. Hospital-based physicians managed significantly more patients with biologics. The initiation of biologic therapy was considered most appropriate following one FESS by the vast majority of respondents. Adherence to guideline-based evaluation criteria for biologic treatment response was suboptimal, highlighting gaps in clinical practice. Our survey highlights strengths in guideline adherence and areas for improvement, particularly in the diagnostic approach, systemic corticosteroid usage, and biologic treatment. Addressing educational gaps and refining clinical practices could enhance patient outcomes, reduce invasive procedures, and optimize resource utilization in CRSwNP management.<\/jats:p>","DOI":"10.1038\/s41598-025-07658-3","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:31:25Z","timestamp":1751423485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current diagnostic and therapeutic management of chronic rhinosinusitis with nasal polyps in Austria: insights and unmet needs from a nationwide survey"],"prefix":"10.1038","volume":"15","author":[{"given":"Katharina","family":"Walla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Habenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Walrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"G\u00fcnzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Valentin","family":"Tomazic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Andrianakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"Suppl S29","key":"7658_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens, W. J. et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl S29), 1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600 (2020).","journal-title":"Rhinology"},{"issue":"6","key":"7658_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2500\/ajra.2013.27.3981","volume":"27","author":"MR Chaaban","year":"2013","unstructured":"Chaaban, M. R., Walsh, E. M. & Woodworth, B. A. Epidemiology and differential diagnosis of nasal polyps. Am. J. Rhinol. Allergy 27(6), 473\u2013478. https:\/\/doi.org\/10.2500\/ajra.2013.27.3981 (2013).","journal-title":"Am. J. Rhinol. Allergy"},{"issue":"11","key":"7658_CR3","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1016\/j.jaip.2021.06.037","volume":"9","author":"NJ Campion","year":"2021","unstructured":"Campion, N. J. et al. Prevalence and symptom burden of nasal polyps in a large Austrian population. J. Allergy Clin. Immunol. Pract. 9(11), 4117\u20134129e2. https:\/\/doi.org\/10.1016\/j.jaip.2021.06.037 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"5","key":"7658_CR4","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","volume":"137","author":"P Tomassen","year":"2016","unstructured":"Tomassen, P. et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J. Allergy Clin. Immunol. 137(5), 1449\u20131456e4. https:\/\/doi.org\/10.1016\/j.jaci.2015.12.1324 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"7658_CR5","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","volume":"7","author":"WW Stevens","year":"2019","unstructured":"Stevens, W. W. et al. Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J. Allergy Clin. Immunol. Pract. 7, 2812\u20132820E3 (2019).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"7658_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw, T. M., Mullol, J., Woessner, K. M., Amin, N. & Mannent, L. P. Chronic rhinosinusitis with nasal polyps and asthma. J. Allergy Clin. Immunol. Pract. 9, 1133\u20131141 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"7658_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.otc.2022.09.008","volume":"56","author":"BK Walters","year":"2023","unstructured":"Walters, B. K. et al. Aspirin-exacerbated respiratory disease and the unified airway: A contemporary review. Otolaryngol. Clin. North. Am. 56(1), 107\u2013124 (2023).","journal-title":"Otolaryngol. Clin. North. Am."},{"issue":"4","key":"7658_CR8","first-page":"CD011996","volume":"4","author":"LY Chong","year":"2016","unstructured":"Chong, L. Y. et al. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst. Rev. 4(4), CD011996 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"7658_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13601-019-0303-6","volume":"10","author":"V Hox","year":"2020","unstructured":"Hox, V. et al. Benefits and harm of systemicsteroids for short- and long-term use in rhinitis and rhinosinusitis: An EAACI position paper. Clin. Transl. Allergy 10, 1 (2020).","journal-title":"Clin. Transl. Allergy"},{"issue":"3","key":"7658_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/lary.26391","volume":"127","author":"AS DeConde","year":"2017","unstructured":"DeConde, A. S. et al. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope 127(3), 550\u2013555 (2017).","journal-title":"Laryngoscope"},{"key":"7658_CR11","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1007\/s00405-024-08832-5","volume":"281","author":"L Levi","year":"2024","unstructured":"Levi, L. et al. Patterns of recurrence in patients with CRSwNP who underwent complete FESS. Eur. Arch. Otorhinolaryngol. 281, 5847\u20135856 (2024).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"7658_CR12","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/"},{"key":"7658_CR13","doi-asserted-by":"publisher","unstructured":"Wang, H. et al. Efficacy of different biologics for treating chronic rhinosinusitis with nasal polyps: A network meta-analysis. Eur. Arch. Otorhinolaryngol. 26 https:\/\/doi.org\/10.1007\/s00405-024-08903-7 (2024).","DOI":"10.1007\/s00405-024-08903-7"},{"issue":"2","key":"7658_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/biomedicines11020485","volume":"11","author":"MS Dom\u00ednguez-Sosa","year":"2023","unstructured":"Dom\u00ednguez-Sosa, M. S. et al. Real-life effectiveness of mepolizumab in refractory chronic rhinosinusitis with nasal polyps. Biomedicines 11(2), 485 (2023).","journal-title":"Biomedicines"},{"issue":"1","key":"7658_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/jpm14010003","volume":"14","author":"N Lombardo","year":"2023","unstructured":"Lombardo, N. et al. Real-life effects of Omalizumab on chronic rhinosinusitis with nasal polyposis. J. Pers. Med. 14(1), 3 (2023).","journal-title":"J. Pers. Med."},{"key":"7658_CR16","unstructured":"Seys, S. F. et al. CHRINOSOR consortium. Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR). J. Allergy Clin. Immunol. (2024)."},{"issue":"3","key":"7658_CR17","first-page":"CD013513","volume":"3","author":"LY Chong","year":"2021","unstructured":"Chong, L. Y. et al. Biologics for chronic rhinosinusitis. Cochrane Database Syst. Rev. 3(3), CD013513 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"7658_CR18","first-page":"194","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens, W. J. et al. EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology 61(3), 194\u2013202 (2023).","journal-title":"Rhinology"},{"issue":"5","key":"7658_CR19","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00405-022-07762-4","volume":"280","author":"J Maza-Solano","year":"2023","unstructured":"Maza-Solano, J. et al. Chronic rhinosinusitis with nasal polyps management in the biologic therapy era: An international YO-IFOS survey. Eur. Arch. Otorhinolaryngol. 280(5), 2309\u20132316 (2023).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"issue":"11","key":"7658_CR20","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/alr.23392","volume":"14","author":"NF Ayoub","year":"2024","unstructured":"Ayoub, N. F., Sbeih, F. & Bleier, B. S. Contemporary practice patterns for chronic rhinosinusitis with nasal polyps. Int. Forum Allergy Rhinol. 14(11), 1830\u20131833 (2024).","journal-title":"Int. Forum Allergy Rhinol"},{"issue":"1","key":"7658_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00405-023-08185-5","volume":"281","author":"I Alobid","year":"2024","unstructured":"Alobid, I. et al. Management of patients with chronic rhinosinusitis with nasal polyps in spain: Learnings from a nationwide survey of otorhinolaryngologists. Eur. Arch. Otorhinolaryngol. 281(1), 227\u2013235 (2024).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"7658_CR22","doi-asserted-by":"crossref","unstructured":"Kim, H. A. J. et al. Assessing the use of Patient-Reported outcome measures in the routine clinical care of chronic rhinosinusitis patients: A Canadian perspective. J. Otolaryngol. Head Neck Surg. 53, 19160216241288806 (2024).","DOI":"10.1177\/19160216241288806"},{"issue":"9","key":"7658_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1055\/a-2246-2793","volume":"103","author":"E Deuss","year":"2024","unstructured":"Deuss, E. et al. Ergebnisse einer umfrage Zur aktuellen behandlung der Chronischen rhinosinusitis Mit Nasalen polypen [Results of a survey on the current management of chronic rhinosinusitis with nasal polyps in Germany]. Laryngorhinootologie 103(9), 646\u2013654 (2024). (German).","journal-title":"Laryngorhinootologie"},{"issue":"3","key":"7658_CR24","first-page":"1","volume":"20","author":"F Bachner","year":"2018","unstructured":"Bachner, F. et al. Austria: Health system review. Health Syst. Trans. 20(3), 1\u2013256 (2018).","journal-title":"Health Syst. Trans."},{"issue":"1","key":"7658_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/alr.21071","volume":"3","author":"M Amine","year":"2013","unstructured":"Amine, M., Lininger, L., Fargo, K. N. & Welch, K. C. Outcomes of endoscopy and computed tomography in patients with chronic rhinosinusitis. Int. Forum Allergy Rhinol. 3(1), 73\u201379 (2013).","journal-title":"Int. Forum Allergy Rhinol"},{"issue":"3","key":"7658_CR26","first-page":"383","volume":"62","author":"R n der Lans","year":"2024","unstructured":"n der Lans, R. et al. Eosinophils are the dominant type2 marker for the current indication of biological treatment in severe uncontrolled chronic rhinosinusitis with nasal polyps. Rhinology 62(3), 383\u2013384 (2024).","journal-title":"Rhinology"},{"issue":"4","key":"7658_CR27","first-page":"328","volume":"61","author":"J Deng","year":"2023","unstructured":"Deng, J. et al. Blood eosinophils to direct oral corticosteroid treatment for patients with nasal polyps\u2014An open label, non-inferiority, randomized control trial. Rhinology 61(4), 328\u2013337 (2023).","journal-title":"Rhinology"},{"issue":"11","key":"7658_CR28","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/pharmaceutics16111370","volume":"16","author":"M Habenbacher","year":"2024","unstructured":"Habenbacher, M. et al. Investigation of blood count-based inflammatory biomarkers as predictors of response to dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps. Pharmaceutics 16(11), 1370 (2024).","journal-title":"Pharmaceutics"},{"issue":"1","key":"7658_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/alr.22636","volume":"11","author":"B Zhong","year":"2021","unstructured":"Zhong, B. et al. The role of preoperative blood eosinophil counts in distinguishing chronic rhinosinusitis with nasal polyps phenotypes. Int. Forum Allergy Rhinol. 11(1), 16\u201323 (2021).","journal-title":"Int. Forum Allergy Rhinol"},{"issue":"3","key":"7658_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/alr.21885","volume":"7","author":"G Brescia","year":"2017","unstructured":"Brescia, G. et al. The prognostic role of serum eosinophil and basophil levels in sinonasal polyposis. Int. Forum Allergy Rhinol. 7(3), 261\u2013267 (2017).","journal-title":"Int. Forum Allergy Rhinol"},{"issue":"5","key":"7658_CR31","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jaip.2019.02.030","volume":"7","author":"M Humbert","year":"2019","unstructured":"Humbert, M. et al. IgE-mediated multimorbidities in allergic asthma and the potential for Omalizumab therapy. J. Allergy Clin. Immunol. Pract. 7(5), 1418\u20131429 (2019).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"7658_CR32","first-page":"125","volume":"50","author":"S Alimuddin","year":"2018","unstructured":"Alimuddin, S., Rengganis, I., Rumende, C. M. & Setiati, S. Comparison of specific immunoglobulin E with the skin Prick test in the diagnosis of house dust mites and cockroach sensitization in patients with asthma and\/or allergic rhinitis. Acta Med. Indones 50(2), 125\u2013131 (2018).","journal-title":"Acta Med. Indones"},{"issue":"1","key":"7658_CR33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12016-021-08901-1","volume":"62","author":"P Gevaert","year":"2022","unstructured":"Gevaert, P., Wong, K., Millette, L. A. & Carr, T. F. The role of IgE in upper and lower airway disease: More than just allergy! Clin. Rev. Allergy Immunol. 62(1), 200\u2013215 (2022).","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"7658_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12931-018-0823-y","volume":"19","author":"CM Philpott","year":"2018","unstructured":"Philpott, C. M. et al. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: Data from the UK National chronic rhinosinusitis epidemiology study. Respir Res. 19(1), 129 (2018).","journal-title":"Respir Res."},{"issue":"10","key":"7658_CR35","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1111\/all.13496","volume":"73","author":"ACA Yii","year":"2018","unstructured":"Yii, A. C. A. et al. Precision medicine in united airways disease: A treatable traits approach. Allergy 73(10), 1964\u20131978 (2018).","journal-title":"Allergy"},{"issue":"9","key":"7658_CR36","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/chemse\/bjw080","volume":"41","author":"ZM Soler","year":"2016","unstructured":"Soler, Z. M., Kohli, P., Storck, K. A. & Schlosser, R. J. Olfactory impairment in chronic rhinosinusitis using threshold, discrimination, and identification scores. Chem. Senses 41(9), 713\u2013719 (2016).","journal-title":"Chem. Senses"},{"issue":"2","key":"7658_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/lary.26316","volume":"127","author":"P Kohli","year":"2017","unstructured":"Kohli, P. et al. The prevalence of olfactory dysfunction in chronic rhinosinusitis. Laryngoscope 127(2), 309\u2013320 (2017).","journal-title":"Laryngoscope"},{"issue":"6","key":"7658_CR38","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/chemse\/bjz029","volume":"44","author":"J L\u00f6tsch","year":"2019","unstructured":"L\u00f6tsch, J. & Hummel, T. Clinical usefulness of self-rated olfactory performance-\u2014A data science-based assessment of 6000 patients. Chem. Senses 44(6), 357\u2013364 (2019).","journal-title":"Chem. Senses"},{"issue":"33","key":"7658_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin22.483","volume":"61","author":"KL Whitcroft","year":"2023","unstructured":"Whitcroft, K. L. et al. Position paper on olfactory dysfunction: 2023. Rhinology 61(33), 1\u2013108 (2023).","journal-title":"Rhinology"},{"issue":"5","key":"7658_CR40","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/all.15982","volume":"79","author":"PW Hellings","year":"2024","unstructured":"Hellings, P. W. et al. EUFOREA\/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care. Allergy 79(5), 1123\u20131133 (2024).","journal-title":"Allergy"},{"issue":"1","key":"7658_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4193\/Rhin17.255","volume":"57","author":"A Khan","year":"2019","unstructured":"Khan, A. et al. The global allergy and asthma European network (GALEN rhinosinusitis cohort: A large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 57(1), 32\u201342 (2019).","journal-title":"Rhinology"},{"issue":"2","key":"7658_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/alr.22487","volume":"10","author":"CA Loftus","year":"2020","unstructured":"Loftus, C. A. et al. Revision surgery rates in chronic rhinosinusitis with nasal polyps: Meta-analysis of risk factors. Int. Forum Allergy Rhinol. 10(2), 199\u2013207 (2020).","journal-title":"Int. Forum Allergy Rhinol"},{"key":"7658_CR43","doi-asserted-by":"crossref","unstructured":"van der Otten, J. et al. Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making. Expert Rev. Clin. Immunol. 19(8), 1041\u20131049 (2023).","DOI":"10.1080\/1744666X.2023.2218617"},{"key":"7658_CR44","doi-asserted-by":"publisher","unstructured":"Dorling, M. et al. Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience. Int. Forum Allergy Rhinol. (2024). https:\/\/doi.org\/10.1002\/alr.23466","DOI":"10.1002\/alr.23466"},{"key":"7658_CR45","unstructured":"https:\/\/www.sozialversicherung.at\/oeko\/views\/index.xhtml"},{"issue":"10","key":"7658_CR46","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.15796","volume":"78","author":"RJL n der Lans","year":"2023","unstructured":"n der Lans, R. J. L. et al. Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months. Allergy 78(10), 2684\u20132697 (2023).","journal-title":"Allergy"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07658-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07658-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07658-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:31:28Z","timestamp":1751423488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07658-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7658"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07658-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Janina Kay is a GSK employee, Philipp Guenzl and Laura Walrave are GSK employees and hold financial equities in GSK. The other authors declare that they have no conflict of interest. The primary market research carried out by IQVIA was financed by GSK Austria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23051"}}